Brilliant Violet 421™ anti-mouse CD80

Antibodies Single
Sony
16-10A1
Flow Cytometry
Hamster IgG
Other
CHO cell line transfected with mouse B7 (CD80)
1123630
$422.00

Description

CD80 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD80 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD80 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD80 appears to be expressed later in the immune response than CD86. CD80 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. For immunohistochemical staining on frozen tissue sections, the suggested use is 5-10 microg/mL. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Harlan DM, et al. 1994. P. Natl. Acad. Sci. USA 91:3137. (IHC)
2. Razi-Wolf Z, et al. 1992. P. Natl. Acad. Sci. USA 89:4210. (Block, IP)
3. Hathcock KS, et al. 1994. J. Exp. Med. 180:631. (Block)
4. Herold KC, et al. 1997. J. Immunol. 158:984. (Block, IHC)
5. Ma XT, et al. 2006. Cancer Res. 66:1169.
6. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC)
7. Lawson BR, et al. 2007. J. Immunol. 178:5366.
8. Turnquist HR, et al. 2007. J. Immunol. 178:7018.
9. Misra RS, et al. 2010. J. Exp Med. 207:1775. PubMed
10. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
11. White AJ, et al. 2014. J. Immunol. 192:2659. PubMed
12. Cowan JE, et al. 2014. J Immunol. 193:1204. PubMed